For investors

Pangenome AI represents a transformative opportunity at the intersection of artificial intelligence and genomic engineering. We are not simply improving existing processes — we are fundamentally redefining how biological systems are designed, engineered, and deployed at scale.

The opportunity

The convergence of AI and synthetic biology is creating unprecedented market opportunities:

• $15+ billion synthetic biology market growing at 28% CAGR.
• $500+ billion pharmaceutical market seeking breakthrough innovation.
• $20+ billion agricultural biotechnology market demanding sustainable solutions.
• 10-year horizon for biological manufacturing to replace traditional chemical processes.

The problem we solve

Current genome engineering approaches suffer from fundamental inefficiencies:

• 70% failure rates in complex genetic modifications.
• 3–5 year development cycles for new biological products.
• $100M+ costs for bringing engineered organisms to market.
• Limited predictability when transferring genes between species.

Traditional trial-and-error methodologies are no longer sustainable in an era demanding rapid innovation and precise biological solutions.

Our solution: the pangenome advantage

Pangenome AI has developed the industry’s first comprehensive AI platform that leverages pangenomic data — the complete genetic diversity within and across species — to design optimal biological systems.

Core innovations

• Large Pangenome Models (LPMs) trained on millions of genomes.
• Predictive compatibility algorithms that eliminate trial-and-error.
• Integrated design-to-manufacturing pipeline reducing time to market by 90%.

Competitive moat

Our defensible market position is built on multiple reinforcing advantages:

1. First-mover advantage in pangenome-scale AI modelling.
2. Proprietary dataset spanning multiple kingdoms of life.
3. Network effects as our models improve with each project.
4. IP portfolio covering novel algorithms and processes.

Business model

Dual revenue strategy

Primary: proprietary product development

• Developing high-value engineered organisms for specific markets.
• Full ownership of IP and product rights.
• Multiple monetisation pathways: licensing, partnerships, or direct commercialisation.

Secondary: platform & services

• Annual platform subscriptions: £50,000 – £500,000.
• Custom design services: £10,000 – £100,000 per project.
• Manufacturing and synthesis services with 40–70% gross margins.

Path to profitability

• Year 1–2 — platform development and validation.
• Year 3–4 — commercial launch and rapid scaling.
• Year 4–5 — break-even with multiple revenue streams.
• Year 5+ — market leadership position with 10–15% market share.

Traction & validation

Scientific foundation

• Leadership team with 130+ peer-reviewed publications.
• Foundational research validated in journal articles.
• Advisory board including leading synthetic biologists and AI researchers.

Commercial progress

• Strategic partnerships in development with major biotech companies.
• Pilot programmes demonstrating 10x improvement in development timelines.
• Strong interest from pharmaceutical and agricultural sectors.

Investment opportunity

Use of proceeds

• Technology development (40%) — expanding AI models to eukaryotic systems, developing automated design-test-learn cycles, and building proprietary genomic datasets.
• Infrastructure (30%) — BSL-2 / BSL-3 laboratory facilities, high-throughput synthesis capabilities, and cloud computing infrastructure.
• Team expansion (20%) — world-class AI and synthetic biology researchers, commercial and business development leadership, and regulatory and quality assurance expertise.
• Operations & marketing (10%) — market development, customer acquisition, regulatory compliance, IP protection, and working capital.

Investment terms

We are raising a Series A round to accelerate our commercial launch and establish market leadership. We welcome strategic investors who bring:

• Deep industry expertise and networks.
• Understanding of long-term value creation in biotech.
• Commitment to transformative rather than incremental innovation.

Leadership team

Professor James McInerney — Co-Founder & Chief Scientific Officer

• PhD, DSc in Genomic Analysis.
• Pioneer in pangenome analysis and horizontal gene transfer.
• 130+ publications with 10,000+ citations.
• Held senior leadership roles at leading research institutions.

Additional team members to be announced.

The path forward

Near-term milestones (12–18 months)

• Complete prokaryotic genome model validation.
• Secure 3–5 strategic commercial partnerships.
• Achieve first product proof-of-concept.
• Expand team to 25+ world-class researchers.

Long-term vision

Pangenome AI will become the essential infrastructure for biological innovation — the platform every researcher, company, and institution relies on to transform biological insights into real-world solutions. We are not just building a company; we are establishing the foundation for the bio-economy of the future.

Connect with us

To learn more about investment opportunities in Pangenome AI, please contact our team at james@pangenome.ai.

All information contained herein is confidential and proprietary to Pangenome AI Limited.